Robust M&A activity through mid-September 2026 reflects strategic consolidation in life sciences and technology, with H1 biotech deals reaching $149 billion across 49 transactions led by oncology and immunology. Patent cliffs threatening $305 billion in pharma revenue, combined with AI infrastructure demand, have driven bolt-on acquisitions and select megadeals, including recent insurance and media transactions. Elevated deal values, supported by corporate balance sheets and private equity, contrast with moderating volumes outside large strategic moves. Key near-term catalysts include regulatory approvals for pending transactions and potential portfolio reshaping ahead of year-end, as traders assess which targets may close before 2027 amid ongoing sector-specific momentum.